HeartWare International Inc (HTWR) reported quarterly earnings results on Thursday, Jul-28-2016. The company said it had a profit of $-0.62 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.19. Analysts had a consensus of $-0.81. The company posted revenue of $68.72 million in the period, compared to analysts expectations of $57.36 million. The company’s revenue was down -6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.47 EPS.
Many Wall Street Analysts have commented on HeartWare International Inc. HeartWare International Inc was Downgraded by Raymond James to ” Mkt Perform” on Jul 13, 2016. HeartWare International Inc was Downgraded by Leerink Partners to ” Mkt Perform” on Jul 11, 2016. HeartWare International Inc was Downgraded by Wells Fargo to ” Market Perform” on Jun 29, 2016.
HeartWare International Inc opened for trading at $57.9 and hit $57.95 on the upside on Thursday, eventually ending the session at $57.89, with a gain of 0.02% or 0.01 points. The heightened volatility saw the trading volume jump to 1,24,142 shares. Company has a market cap of $1,015 M.
In a different news, on Jul 25, 2016, Mark Strong (Senior VP, R&D and Quality) sold 1,875 shares at $57.71 per share price. According to the SEC, on Jul 12, 2016, Peter F Mcaree (SVP, CFO and Treasurer) sold 3,125 shares at $57.68 per share price. On Jul 5, 2016, James Schuermann (SVP, Sales & Marketing) sold 1,000 shares at $57.77 per share price, according to the Form-4 filing with the securities and exchange commission.
Heartware International Inc. is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices for patients suffering from advanced heart failure. The HeartWare Ventricular Assist System (HVAD System) which includes a ventricular assist device (VAD) or blood pump patient accessories and surgical tools provides circulatory support for patients in the advanced stage of heart failure. The core of the HVAD System is a continuous flow blood pump the HVAD pump. The HVAD System is designed to be implanted adjacent to the heart avoiding abdominal surgery directly adjacent to the heart. The Company’s hybrid system is used for suspending the impeller. The impeller is suspended within the pump housing by the opposing forces of passive magnets and hydrodynamic thrust generated by the pump impeller which circulates a cushion of blood.